• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 12
  • 10
  • 6
  • 4
  • 3
  • 3
  • 1
  • Tagged with
  • 43
  • 21
  • 18
  • 16
  • 16
  • 15
  • 14
  • 13
  • 13
  • 13
  • 13
  • 9
  • 9
  • 9
  • 9
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
21

Einfluss zyklischer mechanischer Dehnung auf das Kinin-Kallikrein-System in alveolären Typ-II-Zellen der Ratte

Schweinberger, Anna 08 March 2017 (has links) (PDF)
Beatmungsbedingte Lungenschäden in der Therapie des akuten Atemnotsyndroms (ARDS) sind aufgrund der inhomogenen Vorschädigung der Lunge praktisch unvermeidbar. Die unphysiologische mechanische Belastung der Lunge führt über Volutrauma, Atelektotrauma und Biotrauma nicht selten zur Exazerbation des Syndroms und trägt zur hohen Mortalität des ARDS bei. Pharmakologische Interventionsmöglichkeiten sind Gegenstand der aktuellen Forschung. Diesbezüglich vielversprechend ist die zentrale Komponente des Kinin-Kallikrein-Systems, namentlich Bradykinin, das über seinen B2-Rezeptor anti-apoptotische Signalwege aktivieren kann und somit zellprotektive Wirkung besitzt. In der vorliegenden Arbeit wurde untersucht, in welcher Weise zyklische mechanische Dehnung die Konzentration einzelner Komponenten des Kinin-Kallikrein-Systems in isolierten alveolären Epithelzellen (Typ II) der Ratte beeinflusst. Dafür wurden die alveolären Typ-II-Zellen auf speziellen BioFlex®-Membranen kultiviert und für 24 Stunden zyklisch mit hoher Dehnungsamplitude gedehnt. Anschließend wurden mit etablierten Analysemethoden in Zellüberständen bzw. Zelllysaten die Konzentrationen von Kininogen 1, Bradykinin und vom B2-Rezeptor gemessen, sowie die Aktivität des Enzyms Kallikrein und des Bradykinin-Abbaus bestimmt - jeweils im Vergleich mit Überständen bzw. Lysaten ungedehnter AT-II-Zellkulturen. Es zeigte sich dehnungs-bedingt eine Zunahme der Bradykinin-Produktion durch Kininogen und Kallikrein und eine stark gesteigerte Bradykinin-abbauende Aktivität, sodass sich der Bradykininspiegel insgesamt verringerte. Die Konzentration des B2-Rezeptors blieb unverändert. Detailliertes Wissen über den Einfluss zyklischer mechanischer Dehnung auf die Einzelkomponenten des Kinin-Kallikrein-Systems ist eine Grundvoraussetzung, um die zellprotektive Wirkung von Bradykinin im Sinne einer pharmakologischen Interventionsmöglichkeit bei ARDS nutzbar machen zu können.
22

Caracterização do sistema calicreína-cinina durante o processo ovulatório de bovinos / Characterization of kallikrein-kinin system during the ovulation process in bovine

Ilha, Gustavo Freitas 25 February 2011 (has links)
Conselho Nacional de Desenvolvimento Científico e Tecnológico / The kallikrein-kinin system (KKS) has been described as an important mediator of physiologic processes. Kallikreins use kininogen (KNG) as substrate to generate bradykinin, the principal active peptide of the KKS which acts through two types of receptors, the B1R and B2R. The objective of this study was to characterize some components of KKS in different compartments of ovary during the ovulation process in bovine. mRNA expression pattern of KNG, B1R and B2R was assessed in theca and granulosa cells and bradykinin concentration and kallikrein-like activity in follicular fluid of bovine peri-ovulatory follicles. In order to obtain a peri-ovulatory follicle (≥ 12mm), twenty-seven cows were submitted to estrus synchronization protocol and ovariectomized by colpotomy at 0, 3, 6, 12 or 24 hours after a GnRH-analog injection (gonadorelin; 100 μg, IM). Follicular fluid was aspirated for enzymatic assays and granulosa and theca cells were harvested for mRNA analysis. The mRNA expressions in follicular cells were evaluated by real-time RT-PCR and data represented as relative to housekeeping gene cyclophilin. Bradykinin concentration and Kallikrein-like activity was measured in follicular fluid by enzymatic immunoassay and selective substrate cleavage, respectively, and the absorbance measured using a plate reader. KNG mRNA expression was similar for both follicular cell types (P>0.05), while B2R expression in theca cells and B1R expression in theca and granulosa cells showed different profiles during peri-ovulatory period (P<0.05). Bradykinin concentration and kallikrein-like activity in follicular fluid were different (P<0.05) according the time during ovulation process. The results provide an important characterization of the presence and possible regulation of KKS during ovulation in bovine. / O sistema calicreína-cinina (KKS) tem sido descrito como um importante mediador de processos fisiológicos. Calicreínas utilizam o cininogênio (KNG) como substrato para formar a bradicinina, que é o principal peptídeo ativo do KKS o qual atua através de dois tipos de receptores, o B1R e B2R. O objetivo deste estudo foi caracterizar os principais componentes do KKS em diferentes compartimentos ovarianos durante o processo ovulatório de bovinos. A expressão de RNAm de KNG, B1R e B2R foi mensurada em células da teca e granulosa, e concentração de bradicinina e atividade de calicreína no fluido folicular de folículos peri-ovulatórios bovinos. Para obter um folículo peri-ovulatório (≥ 12mm), vinte e sete vacas foram submetidas a um protocolo de sincronização de cios e ovariectomizadas por colpotomia 0, 3, 6, 12 ou 24 horas após uma injeção de um análogo ao GnRH (gonadorelina; 100 μg, IM). O fluido folicular foi aspirado para os ensaios enzimáticos e as células da teca e granulosa dissecadas para análise do RNAm. A expressão do RNAm em células foliculares foi avaliada por PCR em tempo real e os dados representados em relação ao gene constitutivo ciclofilina. A concentração de bradicinina e atividade de calicreína foram mensuradas no fluido follicular por imunoensaio enzimático e clivagem de substrato seletivo, respectivamente, e sua absorbância mensurada por leitor de placas. A expressão de RNAm para o KNG não variou em ambos os tipos celulares nos diferentes tempos (P>0,05), enquanto que para B2R a expressão em células da teca e expressão para B1R nas células da teca e granulosa apresentaram diferentes padrões durante o período peri-ovulatório (P<0,05). A concentração de bradicinina e a atividade de calicreína no fluido follicular foram diferentes (P<0,05) de acordo com o tempo durante o processo ovulatório. Estes resultados demonstram que o KKS está presente e há indicativos de sua regulação durante a ovulação em bovinos
23

Localisation, mécanisme d’induction et rôle physiopathologique du récepteur B1 des kinines dans de modèles expérimentaux de douleur chez le rat

Talbot, Sébastien 06 1900 (has links)
Les kinines sont des peptides neuro- et vaso- actifs impliqués dans les processus hémodynamiques, inflammatoires et douloureux. Leurs effets biologiques sont produits par l’entremise de deux types de récepteurs couplés aux protéines G, soit B1 (B1R) et B2 (B2R). Le B1R est inductible, son expression est augmentée à la suite d’un dommage tissulaire ou de l’exposition à des endotoxines bactériennes (lipopolysaccharide bactérien (LPS)), à des cytokines pro-inflammatoires (interleukine-1β (IL-1β), facteur de nécrose tumorale-α (TNF-α)) ou à des espèces réactives oxygénées (ROS). Les travaux présentés dans cette thèse avaient pour objectif d’élucider et/ou de raffiner les connaissances sur 1) la localisation, 2) le mécanisme d’induction et 3) le rôle physiopathologique du B1R dans des modèles expérimentaux de douleur chez le rat. Nos données ont permis de démontrer pour la première fois que le B1R est augmenté de façon significative dans la moelle épinière du rat diabétique de type 1 où il est localisé sur les fibres sensorielles de type C, les astrocytes et les cellules de la microglie (1er article). Également, l’inhibition de l’activation des cellules de la microglie supprime les neuropathies diabétiques, l’expression de médiateurs pro-inflammatoires ainsi que l’activité pro-nociceptive du B1R (2e et 3e articles). Finalement, nous avons démontré que la stimulation systémique du TRPV1 par la capsaïcine induit une surexpression du B1R au niveau microgliale, via un mécanisme impliquant l’augmentation de la production de ROS et possiblement de cytokines (4e article). Ces données nous permettent de mieux comprendre les mécanismes impliqués dans l’expression et l’activité du B1R. Aussi, elles nous permettent d’imaginer de nouvelles stratégies pour prévenir l’induction du B1R (inhibition du TRPV1) ou son activité délétère (inhibition de l’activation des cellules de la microglie) dans la douleur inflammatoire et neuropathique. / Kinins are vaso- and neuro-active peptides involved in hemodynamic, inflammatory and pain processes. Their biological effects are mediated by two G Protein Coupled Receptors (GPCR), termed B2R (constitutive) and B1R (inducible). B1R is expressed following tissue damage or exposure to bacterial endotoxin (LPS), pro-inflammatory cytokines (IL-1β, TNF-α) and increased reactive oxygen species (ROS) levels. The objectives of this doctoral thesis were to define 1) the localisation, 2) the mechanism of induction and 3) the pathophysiological role of B1R in experimental models of pain in rat. Our data showed that B1R is significantly upregulated on sensory C fibers, astrocytes and microglia in spinal cord of type 1 diabetic rat (paper #1). Moreover, pharmacological inhibition of microglia reversed diabetic pain neuropathy, reduced levels of pro-inflammatory mediators and prevented B1R pro-nociceptive activity (papers #2 and 3). Finally, our data showed that systemic stimulation of TRPV1 with capsaicin upregulated B1R expression, mainly on microglia, through the increase of ROS and possibly cytokines (paper #4). Altogether, these data increased our knowledge related to B1R mechanism of induction and B1R activity. Also, these data shed light on new strategies to prevent B1R expression (TRPV1 blockade) and B1R deleterious activity (inhibition of microglia activation) in inflammatory and neuropathic pain.
24

Papel da enzima conversora de angiotensina-I na regulação hematopoética de animais normais e nocautes dos receptores B1 de cininas. / Role of angiotensin-I converting enzyme in the regulation of the hematopoietic response normal and kinin receptor B1 kockout mice.

Oliveira, Carlos Rocha 30 April 2008 (has links)
Evidências sobre a presença do sistema renina-angiotensina (SRA) na medula óssea e a possível participação da enzima conversora de angiotensina-I (ECA) na regulação hematopoética tem despertado o interesse da comunidade científica. Como a ECA também é um componente chave do sistema calicreína-cininas (SCC), é possível que elementos deste sistema, possam estar envolvidos no controle hematopoético. Assim, avaliamos a participação da ECA na regulação hematopoética de animais não modificados (WT) e nocautes dos receptores B1 de cininas (KOB1). Para isso, utilizamos técnicas de cultura de células de medula óssea, a saber: os ensaios clonogênicos em soft-ágar para granulócitos e macrófagos (CFU-GM) e o sistema de cultura líquida de longa duração (CLLD). Os resultados mostraram a presença da ECA em células das CLLD e indicaram a participação da enzima na proliferação de progenitores hematopoéticos possivelmente através do controle dos níveis de AcSDKP, pois o tratamento com o tetrapeptídeo e com captopril, reduziu significativamente o número CFU-GM in vitro e in vivo. Quando adicionado às CLLD, o AcSDKP foi capaz de aumentar significativamente a expressão do mRNA da ECA, sugerindo que seus níveis possam controlar a expressão gênica desta enzima. Em relação aos animais KOB1, os resultados mostraram maior atividade da ECA, acompanhado de aumento não significativo da expressão gênica e protéica da enzima. O tratamento das CLLD de animais WT com agonistas de receptores de cininas, não alterou a expressão gênica e a atividade da ECA. Assim, nossos dados sugerem que a ECA participa da regulação hematopoética neste modelo. No entanto, novos estudos serão necessários para a elucidação dos mecanismos envolvidos na expressão e/ou controle da atividade da ECA pelos receptores de cininas. / Evidences on the presence of the renin angiotensin system in the bone marrow and the possible participation of the angiotensin-I converting enzyme (ACE) in the hematopoietic regulation have aroused interest of the scientific community. As the ACE also is a common element of the kallikrein-kinin system (KKS), it is possible that elements of KKS, can be involved in the hematopoietic control. Thus, we evaluated the participation of the ACE on the hematopoietic regulation of wild-type (WT) and kinin receptor B1 knockout mice (KOB1). For this, we use techniques of bone marrow cell culture, to know the clonogenic assays for granulocyte-macrophage (GM-CFU) and the long term bone marrow cultures (LTBMC). The results shown the presence of the ACE in cells from LTBMC and its possible participation on hematopoietic proliferation through the control of AcSDKP levels, therefore the treatment with AcSDKP and captopril, decreased significantly the GM-CFU number in vitro and in vivo. When added to the LTBMC, the AcSDKP increase significantly the expression of ACE mRNA, suggesting that its levels could control the gene expression of this enzyme. In relation to KOB1 mice, the results shown increase of the ACE activity and not significant increase of the gene and protein expression of the enzyme. The treatment of the LTBMC of WT mice with kinins receptors agonists, did not modify the gene expression and the ACE activity. Thus, our data suggesting that ACE participate of the hematopoietic regulation in this model. However, new studies will be necessary to understand the involved mechanisms in the expression and/or control of ACE activity by kinins receptors.
25

Contribution of tachykinin and kinin receptors in central autonomic control of blood pressure and behavioural activity in hypertensive rats

De Brito Pereira, Helaine 05 1900 (has links)
This work aims at studing the role of tachykinin NK-3 receptor (R) and kinin B1R in central autonomic regulation of blood pressure (BP) and to determine whether the B1R is overexpressed and functional in rat models of hypertension by measuring the effect of a B1R agonist on behavioural activity. Assumptions: (1) NK-3R located in the ventral tegmental area (VTA) modulates the mesolimbic dopaminergic system and has a tonic activity in hypertension; (2) B1R is overexpressed in the brain of hypertensive rats and has a tonic activity, which contributes to hypertension via a dopamine mechanism; (3) the inhibition of NK-3R and B1R with selective antagonists, reduces central dopaminergic hyperactivity and reverses hypertension. A model of genetic hypertension and a model of experimental hypertension were used: spontaneously hypertensive rats (SHR, 16 weeks) and Wistar-Kyoto (WKY) rats infused for 14 days with angiotensin II (Ang II) (200 ng / kg / min, subcutaneous (s.c.) with Alzet mini pump). The age-matched untreated WKY rats served as common controls. In the first study (article # 1), the cardiovascular response in SHR was evaluated following intracebroventricular (i.c.v.) and/or intra-VTA injection of an agonist (senktide) and antagonists (SB222200 and R-820) of NK-3R. These responses have also been characterized using selective dopamine antagonists DA-D1R (SCH23390), DA-D2R (raclopride) or non-selective dopamine DA-D2R (haloperidol). Also the VTA has been destroyed by ibotenic acid. The pressor response induced by senktide and the anti-hypertensive response induced by SB222200 or R-820 were more pronounced by intra-VTA. These responses were prevented by pre-treatment with raclopride and haloperidol. The lesion of the VTA has prevented the pressor response relayed by senktide (i.c.v.) and the anti-hypertensive effect of R-820 (i.c.v.). In addition, SB222200 (intra-VTA) prevented the pressor response of senktide (i.c.v.) and conversely, senktide (i.c.v.) prevented the antihypertensive effect of SB222200 (intra-VTA). The second study (article # 2) showed that the B1R antagonist (SSR240612) administered by gavage or i.c.v. reverses hypertension in both models. This anti-hypertensive effect was prevented by raclopride and haloperidol. In contrast, the two B1R antagonists (R-715 and R-954) injected s.c., which do not cross the blood-brain barrier reduced weakly blood pressure in hypertensive rats. In the third study (article # 3), the i.c.v. injection of a selective kinin B1R agonist Sar[DPhe8][des-Arg9]BK caused behavioural responses in SHR and Ang II-treated rats and had no effect in control WKY rats . The responses elicited by B1R agonist were blocked by an antagonist of NK-1 (RP67580), an antagonist of NMDA glutamate receptor (DL-AP5), an inhibitor of nitric oxide synthase (NOS) (L -NNA) as well as raclopride and SCH23390.The responses were modestly affected by the inhibitor of inducible NOS (iNOS). The B1R mRNA (measured by RT-PCR) was significantly increased in the hypothalamus, the VTA and the nucleus accumbens of hypertensive animals (SHR and treated with Ang II) compared with control rats. These neuropharmacological studies suggest that: (1) the NK-3R from the VTA is involved in the maintenance of hypertension in SHR by increasing DA transmission in the midbrain; (2) the B1R in SHR and Ang II-treated rats contributes to hypertension via a central mechanism involving DA-D2R; (3) the central B1R increases locomotor activity and nocifensive behaviours via the release of substance P (NK-1), DA and nitric oxide in both rat models of hypertension. Thus, the brain tachykinin NK-3R and kinin B1R represent potential therapeutic targets for the treatment of hypertension. The modulation of the mesolimbic/mesocortical dopaminergic pathway by these receptors suggests their involvement in other physiological functions (pleasure, motor activity, coordination of the response to stress) and pathophysiology (anxiety, depression). / Ce travail vise à étudier le rôle du récepteur NK-3 des tachykinines (NK-3R) et du récepteur B1 des kinines (B1R) dans la régulation autonomique centrale de la pression artérielle et de déterminer si le B1R est surexprimé et fonctionnel chez le rat hypertendu en mesurant l’effet d’antagoniste B1R sur l’activité comportementale. Hypothèses: (1) le NK-3R localisé dans l’aire tegmentale ventrale (VTA) module l’activité dopaminergique du système mésolimbique et possède une activité tonique dans l’hypertension; (2) le B1R est surexprimé dans le cerveau du rat hypertendu et possède une activité tonique qui contribue à l’hypertension via un mécanisme dopaminergique; (3) l’inhibition des NK-3R et B1R avec des antagonistes sélectifs réduit l’hyperactivité dopaminergique centrale et renverse l’hypertension. Un modèle d’hypertension génétique et un modèle d’hypertension expérimentale ont été utilisés: le rat spontanément hypertendu (SHR, 16 sem) et le rat Wistar Kyoto (WKY) infusé pendant 14 jours avec l’angiotensine II (Ang II) (200 ng/kg/min, s.c. avec mini pompe Alzet). Le rat WKY non traité du même âge a servi de témoin commun. Dans la première étude (article # 1), la réponse cardiovasculaire des SHR a été évaluée à la suite de l’injection i.c.v. et/ou intra-VTA d’un agoniste (senktide) et d’antagonistes (SB222200 et R-820) du NK-3R. Ces réponses ont aussi été caractérisées en utilisant des antagonistes sélectifs des récepteurs DA-D1R (SCH23390), DA-D2R (raclopride) ou non-sélectif DA-D2R (halopéridol). Aussi le VTA a été détruit par l’acide iboténique. La réponse pressive induite par senktide et la réponse anti-hypertensive induite par SB222200 ou R-820 étaient plus marquées par la voie intra-VTA. Ces réponses ont été prévenues par un pré-traitement avec le raclopride et l’halopéridol. La lésion du VTA a prévenu la réponse pressive relayée par le senktide (i.c.v.) ainsi que l’effet anti-hypertenseur du R-820 (i.c.v.). De plus, le SB222200 (intra-VTA) a prévenu la réponse pressive du senktide (i.c.v.) et inversement, le senktide (i.c.v.) a prévenu l’effet anti-hypertenseur du SB222200 (intra-VTA). La deuxième étude (article # 2) a montré que l’antagoniste du B1R (SSR240612) administré par gavage ou i.c.v. renverse l’hypertension artérielle dans les deux modèles. Cet effet dépresseur a été prévenu par le raclopride ainsi que l’halopéridol. Par contre, le traitement avec deux antagonistes du B1R (R-715 et R-954) qui ne traversent pas la barrière hémo-encéphalique a réduit faiblement la pression artérielle chez les rats hypertendus. Dans la troisième étude (article # 3), l’injection i.c.v. d’un agoniste sélectif du B1R, le Sar[DPhe8][des-Arg9]BK a causé des réponses comportementales typiques chez le SHR et le rat traité à l’Ang II mais il n’a pas eu d’effet chez le rat témoin WKY. Les réponses induites par l’agoniste B1R ont été bloquées par un antagoniste du récepteur NK-1(RP67580), un antagoniste du récepteur NMDA du glutamate (DL-AP5), un inhibiteur des synthétases du monoxyde d’azote (NOS) (L-NNA) ainsi qu’avec le raclopride et le SCH23390. Les réponses ont été modestement influencées par l’inhibiteur de la NOS inductible (iNOS). L’ARNm du B1R (mesuré par RT-PCR) était significativement augmenté dans l’hypothalamus, le VTA et le noyau accumbens des animaux hypertendus (SHR et traités à l’Ang II) comparativement aux rats témoins. Ces études neuropharmacologiques suggèrent : (1) que le NK-3R du VTA est impliqué dans le maintien de l’hypertension chez le SHR en augmentant la transmission DA au niveau du mésenséphale. (2) Le B1R chez le SHR et les rats traités à l’Ang II contribue à l’hypertension artérielle via un mécanisme central impliquant le DA-D2R. (3) le B1R central augmente l’activité locomotrice et les comportements défensifs, via la relâche de substance P (NK-1), de DA et de NO dans un modèle d’hypertension génétique et expérimental chez le rat. Ainsi, les récepteurs cérébraux NK-3 des tachykinines et B1 des kinines représentent des cibles thérapeutiques potentielles pour le traitement de l’hypertension artérielle. La modulation de la voie dopaminergique mésolimbique/mésocorticale par ces récepteurs suggère une participation dans d’autres fonctions physiologiques (plaisir, activité motrice, coordination de la réponse au stress) et en pathophysiologie (anxiété, dépression).
26

Localisation, mécanisme d’induction et rôle physiopathologique du récepteur B1 des kinines dans de modèles expérimentaux de douleur chez le rat

Talbot, Sébastien 06 1900 (has links)
Les kinines sont des peptides neuro- et vaso- actifs impliqués dans les processus hémodynamiques, inflammatoires et douloureux. Leurs effets biologiques sont produits par l’entremise de deux types de récepteurs couplés aux protéines G, soit B1 (B1R) et B2 (B2R). Le B1R est inductible, son expression est augmentée à la suite d’un dommage tissulaire ou de l’exposition à des endotoxines bactériennes (lipopolysaccharide bactérien (LPS)), à des cytokines pro-inflammatoires (interleukine-1β (IL-1β), facteur de nécrose tumorale-α (TNF-α)) ou à des espèces réactives oxygénées (ROS). Les travaux présentés dans cette thèse avaient pour objectif d’élucider et/ou de raffiner les connaissances sur 1) la localisation, 2) le mécanisme d’induction et 3) le rôle physiopathologique du B1R dans des modèles expérimentaux de douleur chez le rat. Nos données ont permis de démontrer pour la première fois que le B1R est augmenté de façon significative dans la moelle épinière du rat diabétique de type 1 où il est localisé sur les fibres sensorielles de type C, les astrocytes et les cellules de la microglie (1er article). Également, l’inhibition de l’activation des cellules de la microglie supprime les neuropathies diabétiques, l’expression de médiateurs pro-inflammatoires ainsi que l’activité pro-nociceptive du B1R (2e et 3e articles). Finalement, nous avons démontré que la stimulation systémique du TRPV1 par la capsaïcine induit une surexpression du B1R au niveau microgliale, via un mécanisme impliquant l’augmentation de la production de ROS et possiblement de cytokines (4e article). Ces données nous permettent de mieux comprendre les mécanismes impliqués dans l’expression et l’activité du B1R. Aussi, elles nous permettent d’imaginer de nouvelles stratégies pour prévenir l’induction du B1R (inhibition du TRPV1) ou son activité délétère (inhibition de l’activation des cellules de la microglie) dans la douleur inflammatoire et neuropathique. / Kinins are vaso- and neuro-active peptides involved in hemodynamic, inflammatory and pain processes. Their biological effects are mediated by two G Protein Coupled Receptors (GPCR), termed B2R (constitutive) and B1R (inducible). B1R is expressed following tissue damage or exposure to bacterial endotoxin (LPS), pro-inflammatory cytokines (IL-1β, TNF-α) and increased reactive oxygen species (ROS) levels. The objectives of this doctoral thesis were to define 1) the localisation, 2) the mechanism of induction and 3) the pathophysiological role of B1R in experimental models of pain in rat. Our data showed that B1R is significantly upregulated on sensory C fibers, astrocytes and microglia in spinal cord of type 1 diabetic rat (paper #1). Moreover, pharmacological inhibition of microglia reversed diabetic pain neuropathy, reduced levels of pro-inflammatory mediators and prevented B1R pro-nociceptive activity (papers #2 and 3). Finally, our data showed that systemic stimulation of TRPV1 with capsaicin upregulated B1R expression, mainly on microglia, through the increase of ROS and possibly cytokines (paper #4). Altogether, these data increased our knowledge related to B1R mechanism of induction and B1R activity. Also, these data shed light on new strategies to prevent B1R expression (TRPV1 blockade) and B1R deleterious activity (inhibition of microglia activation) in inflammatory and neuropathic pain.
27

Efeitos da obesidade no sistema calicreína-cininas: estudo dos receptores B1 e B2 de cininas em tecido adiposo humano e murino / Effects of obesity on the kallikrein-kinin system: Studies of human and murine B1 and B2 kinin receptors in adipose tissue

Hilzendeger, Aline Mourão [UNIFESP] 28 June 2006 (has links) (PDF)
Made available in DSpace on 2015-07-22T20:50:00Z (GMT). No. of bitstreams: 0 Previous issue date: 2006-06-28. Added 1 bitstream(s) on 2015-08-11T03:25:41Z : No. of bitstreams: 1 Publico-091.pdf: 651136 bytes, checksum: 35401eae81afb55be34c6f47a332e47e (MD5) / Objetivo: Estudar o efeito da obesidade na regulação do sistema calicreína-cininas por meio da expressão dos receptores B1 e B2 de cininas em humanos e camundongos, e as alterações na síntese e funcionalidade dos receptores em tecidos murinos. Métodos: Foram coletados tecido adiposo branco humano e diferentes tecidos de camundongo. Desses tecidos foi extraído o RNA e analisada a expressão dos receptores de cinina por meio da reação em cadeia da polimerase em tempo real. Tecidos como estômago e aorta de camundongos ob/ob e selvagens foram utilizados para extração de proteínas e estudos fisiológicos. Por Western Blotting estudou-se a quantidade de receptor produzida nos animais. O fundus de estômago e aorta abdominal foram utilizados para se obter registros de contrações isométricas para determinação da potência e eficácia dos agonistas em camundongos obesos e magros. Foram aplicadas doses crescentes cumulativas dos agonistas peptídicos dos receptores B1 e B2, bradicinina e des-Arg9-bradicinina. Resultados: Nos experimentos de PCR em tempo real, a expressão gênica dos receptores B1 e B2 de cininas foi mostrada alterada em alguns tecidos dos animais deficientes na produção do hormônio leptina em relação ao controle. Nos tecidos: adiposo branco, aorta, fígado, hipotálamo e estômago, a expressão do receptor B1 apresentou-se aumentada, porém em tecido cardíaco e tecido adiposo marrom, essa estava diminuída. O receptor B2 teve expressão diminuída em tecido adiposo branco e hipotálamo. Nos demais tecidos estudados não houve alteração da expressão do receptor B2. Em humanos, esses receptores apresentaram-se alterados em indivíduos obesos. O estudo foi realizado em tecido adiposo humano de duas regiões de depósito diferentes, visceral e subcutâneo. Foi observada diferença na expressão do mesmo tecido, porém de regiões distintas. Nos tecidos dos camundongos obesos a resposta aos agonistas dos receptores B1 e B2, bradicinina e des-Arg9-bradicinina, respectivamente, foi mostrada diminuida. Em fundus de estômago foi observada diminuição significativa na resposta ao agonista BK em animais obesos e tratados com dieta hiperlipídica. Tais efeitos podem ser devido às conseqüências do aumento excessivo de peso, como inflamação crônica apresentada nesses animais, ou mesmo devido a diabetes tipo II, a qual consiste em uma patologia diretamente relacionada à obesidade, sugerida neste trabalho como fator capaz de alterar a ação do sistema calicreína-cininas em determinados tecidos. Conclusão: Análises de expressão gênica mostraram que a obesidade afeta os receptores de cinina em diversos tecidos de camundongo, assim como em humanos. Análises fisiológicas funcionais mostraram diminuição na resposta ao agonista de B1 em animais obesos. Os dados deste trabalho sugerem que a obesidade afeta a modulação do sistema calicreína-cininas em modelo murino e humano. Dessa forma, uma possível interação entre obesidade e sistema calicreína-cininas poderia estar envolvida nesta patologia, assim como ser um fator para desenvolvimento a sindrome metabólica. / Objectives: To study the effect of obesity on the kallikrein-kinin system through the expression of receptors B1 and B2 on humans and mice, and alterations in the synthesis and functionality of the receptor in murine tissues. Methods: white human adipose tissue and different kinds of mice tissues were collected. RNA was extracted and the kinin receptors expression analyzed through a real-time polymerase chain reaction. Tissues and organs such as stomach and aorta were used for protein extraction and physiological studies. By Western Blotting, receptor quantitation was studied. Stomach fungus and abdominal aorta were used to register isometric contractions to determine the potency and effectiveness of the agonists on obese and control mice. Increasing accumulating doses of bradykinin and des-Arg9-bradykinin, B2 and B1 receptors agonists respectively, were applied. Results: In the real-time PCR experiments, the gene expression of the B1 and B2 receptors were altered in some tissues of the animals deficient for leptin, when compared to the control. In the white adipose tissue, aorta, liver, hypothalamus and stomach, the B1 receptor expression was increased, but in cardiac tissues and brown adipose tissue, it was decreased. The expression of B2 receptor was decreased in white adipose tissue and hypothalamus. In the other studied tissues, no changes was detected in the B2 receptor expression. In humans, these receptors were altered in obese individuals. The study was performed in human adipose tissue from two different regions of depots, visceral and subcutaneous. There was a tendency of different expression in the same tissue, but from different areas. In tissues from obese mice the response to the B2 and B1 agonists, bradykinin and des-Arg9-bradykinin, respectively, had a decreasing tendency. A significant decrease was observed in stomach fundus in response to the BK agonist. Such effects can be due to the increased weight and its consequences, such as chronic inflammation or diabetes type II, which is a pathology directly related to obesity. Conclusion: expression and functional analysis show that obesity affects kinin receptors in many different mouse tissues as well as in humans. / TEDE / BV UNIFESP: Teses e dissertações
28

Papel da enzima conversora de angiotensina-I na regulação hematopoética de animais normais e nocautes dos receptores B1 de cininas. / Role of angiotensin-I converting enzyme in the regulation of the hematopoietic response normal and kinin receptor B1 kockout mice.

Carlos Rocha Oliveira 30 April 2008 (has links)
Evidências sobre a presença do sistema renina-angiotensina (SRA) na medula óssea e a possível participação da enzima conversora de angiotensina-I (ECA) na regulação hematopoética tem despertado o interesse da comunidade científica. Como a ECA também é um componente chave do sistema calicreína-cininas (SCC), é possível que elementos deste sistema, possam estar envolvidos no controle hematopoético. Assim, avaliamos a participação da ECA na regulação hematopoética de animais não modificados (WT) e nocautes dos receptores B1 de cininas (KOB1). Para isso, utilizamos técnicas de cultura de células de medula óssea, a saber: os ensaios clonogênicos em soft-ágar para granulócitos e macrófagos (CFU-GM) e o sistema de cultura líquida de longa duração (CLLD). Os resultados mostraram a presença da ECA em células das CLLD e indicaram a participação da enzima na proliferação de progenitores hematopoéticos possivelmente através do controle dos níveis de AcSDKP, pois o tratamento com o tetrapeptídeo e com captopril, reduziu significativamente o número CFU-GM in vitro e in vivo. Quando adicionado às CLLD, o AcSDKP foi capaz de aumentar significativamente a expressão do mRNA da ECA, sugerindo que seus níveis possam controlar a expressão gênica desta enzima. Em relação aos animais KOB1, os resultados mostraram maior atividade da ECA, acompanhado de aumento não significativo da expressão gênica e protéica da enzima. O tratamento das CLLD de animais WT com agonistas de receptores de cininas, não alterou a expressão gênica e a atividade da ECA. Assim, nossos dados sugerem que a ECA participa da regulação hematopoética neste modelo. No entanto, novos estudos serão necessários para a elucidação dos mecanismos envolvidos na expressão e/ou controle da atividade da ECA pelos receptores de cininas. / Evidences on the presence of the renin angiotensin system in the bone marrow and the possible participation of the angiotensin-I converting enzyme (ACE) in the hematopoietic regulation have aroused interest of the scientific community. As the ACE also is a common element of the kallikrein-kinin system (KKS), it is possible that elements of KKS, can be involved in the hematopoietic control. Thus, we evaluated the participation of the ACE on the hematopoietic regulation of wild-type (WT) and kinin receptor B1 knockout mice (KOB1). For this, we use techniques of bone marrow cell culture, to know the clonogenic assays for granulocyte-macrophage (GM-CFU) and the long term bone marrow cultures (LTBMC). The results shown the presence of the ACE in cells from LTBMC and its possible participation on hematopoietic proliferation through the control of AcSDKP levels, therefore the treatment with AcSDKP and captopril, decreased significantly the GM-CFU number in vitro and in vivo. When added to the LTBMC, the AcSDKP increase significantly the expression of ACE mRNA, suggesting that its levels could control the gene expression of this enzyme. In relation to KOB1 mice, the results shown increase of the ACE activity and not significant increase of the gene and protein expression of the enzyme. The treatment of the LTBMC of WT mice with kinins receptors agonists, did not modify the gene expression and the ACE activity. Thus, our data suggesting that ACE participate of the hematopoietic regulation in this model. However, new studies will be necessary to understand the involved mechanisms in the expression and/or control of ACE activity by kinins receptors.
29

Expression, distribution et fonction du récepteur B1 des kinines dans la rétine lors du diabète et de la néovascularisation choroïdienne chez le rat

Hachana, Soumaya 11 1900 (has links)
No description available.
30

Einfluss zyklischer mechanischer Dehnung auf das Kinin-Kallikrein-System in alveolären Typ-II-Zellen der Ratte

Schweinberger, Anna 09 February 2017 (has links)
Beatmungsbedingte Lungenschäden in der Therapie des akuten Atemnotsyndroms (ARDS) sind aufgrund der inhomogenen Vorschädigung der Lunge praktisch unvermeidbar. Die unphysiologische mechanische Belastung der Lunge führt über Volutrauma, Atelektotrauma und Biotrauma nicht selten zur Exazerbation des Syndroms und trägt zur hohen Mortalität des ARDS bei. Pharmakologische Interventionsmöglichkeiten sind Gegenstand der aktuellen Forschung. Diesbezüglich vielversprechend ist die zentrale Komponente des Kinin-Kallikrein-Systems, namentlich Bradykinin, das über seinen B2-Rezeptor anti-apoptotische Signalwege aktivieren kann und somit zellprotektive Wirkung besitzt. In der vorliegenden Arbeit wurde untersucht, in welcher Weise zyklische mechanische Dehnung die Konzentration einzelner Komponenten des Kinin-Kallikrein-Systems in isolierten alveolären Epithelzellen (Typ II) der Ratte beeinflusst. Dafür wurden die alveolären Typ-II-Zellen auf speziellen BioFlex®-Membranen kultiviert und für 24 Stunden zyklisch mit hoher Dehnungsamplitude gedehnt. Anschließend wurden mit etablierten Analysemethoden in Zellüberständen bzw. Zelllysaten die Konzentrationen von Kininogen 1, Bradykinin und vom B2-Rezeptor gemessen, sowie die Aktivität des Enzyms Kallikrein und des Bradykinin-Abbaus bestimmt - jeweils im Vergleich mit Überständen bzw. Lysaten ungedehnter AT-II-Zellkulturen. Es zeigte sich dehnungs-bedingt eine Zunahme der Bradykinin-Produktion durch Kininogen und Kallikrein und eine stark gesteigerte Bradykinin-abbauende Aktivität, sodass sich der Bradykininspiegel insgesamt verringerte. Die Konzentration des B2-Rezeptors blieb unverändert. Detailliertes Wissen über den Einfluss zyklischer mechanischer Dehnung auf die Einzelkomponenten des Kinin-Kallikrein-Systems ist eine Grundvoraussetzung, um die zellprotektive Wirkung von Bradykinin im Sinne einer pharmakologischen Interventionsmöglichkeit bei ARDS nutzbar machen zu können.:Inhaltsverzeichnis………………………………………………………………………3 1. Einleitung ..................................................................................7 1.1. Zyklische Dehnung der Lunge als physiologischer Stimulus ..........7 1.2. Zyklische Dehnung der Lunge als pathologischer Stimulus ..........8 1.2.1. Beatmungsbedingte Lungenschäden ..................................9 1.2.1.1. Pathomechanismen ..........................................................9 A) Barotrauma und Volutrauma ..................................................9 B) Atelektotrauma .........................................................................10 C) Biotrauma und Mechanotransduktion 11 D) Sauerstofftrauma .................................................................11 1.2.2. Das akute Atemnotsyndrom (ARDS)...................................12 1.2.2.1. Definition/Diagnosekriterien des ARDS................................12 1.2.2.2. Ätiologie und Inzidenz des ARDS .................................13 1.2.2.3. Verlauf des ARDS .........................................................13 1.2.2.4. Therapie des ARDS .........................................................15 1.3. Das Kinin-Kallikrein-System des Menschen .................................17 1.3.1. Komponenten .................................................................18 A) Kallikrein .................................................................................18 B) Kininogen .................................................................................19 C) Bradykinin .........................................................................19 D) Bradykinin-Rezeptoren .........................................................20 1.4. Das Kinin-Kallikrein-System der Ratte .................................22 2. Fragestellungen und Ziele der Studie .........................................23 3. Material und Methoden .........................................................25 3.1. Materialien .........................................................................25 Tabelle 1: Reagenzien und Chemikalien .........................................25 Tabelle 2: Lösungen, Puffer und Kulturmedien .................................27 Tabelle 3: Assays .........................................................................28 Tabelle 4: Geräte und Arbeitsmittel .................................................29 Tabelle 5: Computer-Software .........................................................31 3.2. Methoden .................................................................................31 3.2.1. Zellkultur .........................................................................31 3.2.1.1. Isolierung der AT-II-Zellen aus der Ratte .........................31 3.2.1.2. Kultivierung der AT-II-Zellen .........................................33 3.2.2. Dehnungsexperiment .................................................34 3.2.3. Gewinnung von Analysematerial .................................36 3.2.4. Auswertung der Experimente .........................................37 3.2.4.1. Bestimmung des Proteingehaltes .................................37 3.2.4.2. Bestimmung der Kininogen-Konzentration .........................38 3.2.4.3. Bestimmung der Kallikrein-Aktivität mittels Fluoreszenzspektroskopie .................................................................39 3.2.4.4. Bestimmung der Bradykinin-Konzentration .................40 3.2.4.5. Bestimmung der Bradykinin-abbauenden Aktivität .........42 3.2.4.6. Konzentrationsbestimmung des Bradykinin-Rezeptors 2......44 3.2.5. Statistik .........................................................................45 4. Ergebnisse .........................................................................46 4.1. Beeinflussung des Kinin-Kallikrein-Systems .........................46 4.1.1. Kininogen .........................................................................46 4.1.2. Kallikrein .........................................................................48 4.1.3. Bradykinin-Konzentration .................................................50 4.1.4. Bradykinin-Abbau .........................................................51 4.1.5. Bradykinin-Rezeptor 2 .................................................54 4.2. Zusammenfassung der Ergebnisse .........................................55 5. Diskussion .........................................................................56 5.1. Diskussion der Methoden .........................................................56 5.1.1. Dehnexperiment .........................................................56 5.1.2. Zellkultur .........................................................................59 5.2. Diskussion der Ergebnisse .........................................................59 5.2.1. Die Beeinflussung der Bradykinin-Konzentration durch zyklische mechanische Dehnung ..................................................................59 5.2.2. Die Beeinflussung der Bradykinin-bildenden Komponenten durch zyklische mechanische Dehnung ....................................................61 5.2.3. Die Beeinflussung des Bradykinin-Abbaus durch zyklische mechanische Dehnung ....................................................................65 5.2.4. Die Beeinflussung des Bradykinin-Rezeptors 2 durch zyklische mechanische Dehnung .....................................................................69 5.2.5. Bedeutung der dehnungsinduzierten Aktivierung des Kinin-Kallikrein-Systems .............................................................72 5.3. Schlussbetrachtungen und Ausblick .............................................75 6. Zusammenfassung .....................................................................78 7. Literaturverzeichnis .....................................................................81 8. Abbildungs- und Tabellenverzeichnis .............................................96 9. Abkürzungsverzeichnis .............................................................98 10. Erklärung über die eigenständige Abfassung der Arbeit ...........101 11. Curriculum vitae ...................................................................102 12. Danksagung ...........................................................................103

Page generated in 0.0286 seconds